Showing results (141-150 of 185) with videos related to

Sort By:
Pageof 19
The Journal of Infection|October 5, 2019
S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccineHelen S Marshall, James Baber, Peter Richmond, et al.
Vaccine|January 30, 2019
Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccineTerry Nolan, Maria Elena Santolaya, Ferdinandus de Looze, et al.
Vaccine|February 25, 2015
A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adultsMichael Nissen, Helen Marshall, Peter Richmond, et al.
BMJ Open|May 9, 2019
B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of Neisseria meningitidisHelen S Marshall, Mark McMillan, Ann Koehler, et al.
Vaccine|September 23, 2022
A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)Natalie Banniettis, Jacek Wysocki, Leszek Szenborn, et al.
Vaccine|October 20, 2019
Infant, maternal and demographic predictors of delayed vaccination: A population-based cohort studyHeather F Gidding, Lloyd K Flack, Sarah Sheridan, et al.
AIDS (London, England)|March 20, 2023
A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIVMarissa Wilck, Shaun Barnabas, Kulkanya Chokephaibulkit, et al.
Annals of Neurology|November 23, 2019
SCN1A Variants in vaccine-related febrile seizures: A prospective studyJohn A Damiano, Lucy Deng, Wenhui Li, et al.
Vaccine|December 15, 2022
A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)Androniki Bili, Scott Dobson, Jeffrey Quinones, et al.
Blood Advances|November 16, 2022
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) studyCharles T Quinn, Richard T Wiedmann, Daniel Jarovsky, et al.
Pageof 19